Minocycline Development for Acute Ischemic Stroke

Overview

Journal Transl Stroke Res

Publisher Springer

Date 2011 Sep 13

PMID 21909339

Citations 52

Authors

Susan C Fagan

Lydia E Cronic

David C Hess

Affiliations

Soon will be listed here.

Abstract

Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood-brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.

Citing Articles

Structure-Function Correlation in Cobalt-Induced Brain Toxicity.

Obied B, Richard S, Zahavi A, Fixler D, Girshevitz O, Goldenberg-Cohen N Cells. 2024; 13(21.

PMID: 39513872 PMC: 11545114. DOI: 10.3390/cells13211765.

Beyond nimodipine: advanced neuroprotection strategies for aneurysmal subarachnoid hemorrhage vasospasm and delayed cerebral ischemia.

Luzzi S, Kuru Bektasoglu P, Dogruel Y, Gungor A Neurosurg Rev. 2024; 47(1):305.

PMID: 38967704 PMC: 11226492. DOI: 10.1007/s10143-024-02543-5.

Periodontal Disease Treatment After Stroke or Transient Ischemic Attack: The PREMIERS Study, a Randomized Clinical Trial.

Sen S, Curtis J, Hicklin D, Nichols C, Glover S, Merchant A Stroke. 2023; 54(9):2214-2222.

PMID: 37548008 PMC: 10668075. DOI: 10.1161/STROKEAHA.122.042047.

After Ischemic Stroke, Minocycline Promotes a Protective Response in Neurons via the RNA-Binding Protein HuR, with a Positive Impact on Motor Performance.

Pawletko K, Jedrzejowska-Szypulka H, Bogus K, Pascale A, Fahmideh F, Marchesi N Int J Mol Sci. 2023; 24(11).

PMID: 37298395 PMC: 10253390. DOI: 10.3390/ijms24119446.

Neuroinflammation and brain-peripheral interaction in ischemic stroke: A narrative review.

Cheng W, Zhao Q, Li C, Xu Y Front Immunol. 2023; 13:1080737.

PMID: 36685518 PMC: 9849888. DOI: 10.3389/fimmu.2022.1080737.

References

Lin S, Zhang Y, Dodel R, Farlow M, Paul S, Du Y . Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett. 2001; 315(1-2):61-4. DOI: 10.1016/s0304-3940(01)02324-2. View

Gordon P, Moore D, Gelinas D, Qualls C, Meister M, Werner J . Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology. 2004; 62(10):1845-7. DOI: 10.1212/01.wnl.0000125321.92112.7e. View

Alano C, Kauppinen T, Valls A, Swanson R . Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A. 2006; 103(25):9685-90. PMC: 1480467. DOI: 10.1073/pnas.0600554103. View

Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M . Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke. 2008; 39(3):951-8. DOI: 10.1161/STROKEAHA.107.495820. View

Fagan S, Waller J, Nichols F, Edwards D, Pettigrew L, Clark W . Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke. 2010; 41(10):2283-7. PMC: 3916214. DOI: 10.1161/STROKEAHA.110.582601. View

Zhang W, Narayanan M, Friedlander R . Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003; 53(2):267-70. DOI: 10.1002/ana.10476. View

Saivin S, Houin G . Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988; 15(6):355-66. DOI: 10.2165/00003088-198815060-00001. View

Rosenberg G, Navratil M, Barone F, Feuerstein G . Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996; 16(3):360-6. DOI: 10.1097/00004647-199605000-00002. View

Weng Y, Kriz J . Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia. Exp Neurol. 2007; 204(1):433-42. DOI: 10.1016/j.expneurol.2006.12.003. View

10.

Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan P, Koistinaho J . A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 1999; 96(23):13496-500. PMC: 23976. DOI: 10.1073/pnas.96.23.13496. View

11.

Xu L, Fagan S, Waller J, Edwards D, Borlongan C, Zheng J . Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004; 4:7. PMC: 415551. DOI: 10.1186/1471-2377-4-7. View

12.

Chen M, Ona V, Li M, Ferrante R, Fink K, Zhu S . Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000; 6(7):797-801. DOI: 10.1038/77528. View

13.

Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J . Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res. 2007; 1188:198-206. DOI: 10.1016/j.brainres.2007.10.052. View

14.

Matsukawa N, Yasuhara T, Hara K, Xu L, Maki M, Yu G . Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci. 2009; 10:126. PMC: 2762982. DOI: 10.1186/1471-2202-10-126. View

15.

Colovic M, Caccia S . Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 791(1-2):337-43. DOI: 10.1016/s1570-0232(03)00247-2. View

16.

Wang C, Yang T, Shuaib A . Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res. 2003; 963(1-2):327-9. DOI: 10.1016/s0006-8993(02)04045-3. View

17.

He Y, Appel S, Le W . Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 2001; 909(1-2):187-93. DOI: 10.1016/s0006-8993(01)02681-6. View

18.

Sathasivam S, Grierson A, Shaw P . Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. Neuropathol Appl Neurobiol. 2005; 31(5):467-85. DOI: 10.1111/j.1365-2990.2005.00658.x. View

19.

Du Y, Ma Z, Lin S, Dodel R, Gao F, Bales K . Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A. 2001; 98(25):14669-74. PMC: 64739. DOI: 10.1073/pnas.251341998. View

20.

Elewa H, Hilali H, Hess D, Machado L, Fagan S . Minocycline for short-term neuroprotection. Pharmacotherapy. 2006; 26(4):515-21. PMC: 3171989. DOI: 10.1592/phco.26.4.515. View